Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Global Offices Update: China Approval Imminent, India On The Horizon

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA is making headway in its efforts to establish U.S. regulatory offices overseas, with final approval in China imminent and a proposal for offices in India in final stages of U.S. approval

You may also be interested in...



U.S. FDA To Open Offices In China As Early As September; India Next

U.S. and China are close to finalizing plans to open U.S. FDA offices in China, and FDA could have "boots on the ground" as early as September, according to Murray Lumpkin, FDA's deputy commissioner for international and special Programs

U.S. FDA To Open Offices In China As Early As September; India Next

U.S. and China are close to finalizing plans to open U.S. FDA offices in China, and FDA could have "boots on the ground" as early as September, according to Murray Lumpkin, FDA's deputy commissioner for international and special Programs

China Government Report On Drug Regulation Seeks To Increase Transparency

BEIJING - As part of a drive to open China's drug regulatory system to public scrutiny and foster international cooperation, the Chinese government has released a ground-breaking report on the current state of its industry oversight

Related Content

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel